A Phase 2 interventional study of Decitabine in Acute Myeloid Leukemia, sponsored by Eisai Inc.. Completed at 3 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 36th largest by enrollment of the 120 interventional ones that give a count, is one of 4 that started in 2005, is one of 53 in phase 2, and was the 7th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Portugal, Spain
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages up to 21
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
David Avigan · Sites in United States
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 72 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 32 across the 120 interventional studies. Of the 67 that completed or were terminated, 39 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
6 of the studies testing decitabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06129734Benjamin TomlinsonDecitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | 2027-03 |
| NCT05190471Bio-Path Holdings, Inc.A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | 2027-03 |
| NCT05222984City of Hope Medical CenterNavitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | 2027-03-02 |
| NCT07012044National Cancer Institute (NCI)A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | 2027-03-31 |
| NCT07374029David AviganAdoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Decitabine
20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
Also known as: Dacogen
Complete Response = Morphologic Complete Remission (mCR)
Time frame: 1 year
| Milestone | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Started | 55 |
| Completed | 5 |
| Not completed | 50 |
| Withdrew: Progressive disease | 21 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 11 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Physician decision | 6 |
| Withdrew: Patient not eligible for study | 1 |
| Participants | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Complete Response = Morphologic Complete Remission (mCR) | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine 20 mg/m2 Intravenous | — | 40/55 (72.7%) | 55/55 (100%) |
| Event | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 13/55 |
| Disease ProgressionGeneral disorders | 9/55 |
| SepsisInfections and infestations | 8/55 |
| PneumoniaInfections and infestations | 7/55 |
| BacteraemiaInfections and infestations | 6/55 |
| NeutropeniaBlood and lymphatic system disorders | 4/55 |
| PyrexiaGeneral disorders | 4/55 |
| Clostridium Difficile ColitisInfections and infestations | 4/55 |
| Urinary Tract InfectionInfections and infestations | 4/55 |
| DiarrheaGastrointestinal disorders | 3/55 |
| Event | Decitabine 20 mg/m2 Intravenous |
|---|---|
| FatigueGeneral disorders | 37/55 |
| NauseaGastrointestinal disorders | 28/55 |
| PyrexiaGeneral disorders | 24/55 |
| ConstipationGastrointestinal disorders | 23/55 |
| DiarrheaGastrointestinal disorders | 22/55 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/55 |
| Oedema PeripheralGeneral disorders | 20/55 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 17/55 |
| AstheniaGeneral disorders | 17/55 |
| VomitingGastrointestinal disorders | 16/55 |
| Age, Categorical(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 48 |
| Age Continuous(years) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Mean | 73.0 ± 6.84 |
| Sex: Female, Male(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Female | 28 |
| Male | 27 |
| Race (NIH/OMB)(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 50 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| United States | 55 |
The record gives a start of Mar 2005, a primary completion of Feb 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine